Peer-reviewed veterinary case report
Osaterone acetate effects on semen and prostate fluid in dogs with BPH
By Ferré-Dolcet, Lluis et al.·Published in Reproduction in domestic animals = Zuchthygiene·2022·Department of Animal Medicine, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prostatic fluid composition and semen quality in dogs with benign prostatic hyperplasia undergoing treatment with osaterone acetate.
- Species:
- dog
Plain-English summary
Eight intact male dogs aged 5 to 11 years with benign prostatic hyperplasia (BPH) were treated with osaterone acetate, a medication that helps reduce prostate size. After starting treatment, the dogs showed a significant decrease in prostate volume and improvements in semen quality over time. Initially, there were some issues with sperm quality, but these improved as treatment continued, particularly with an increase in zinc levels in the prostatic fluid, which is important for healthy sperm. This suggests that osaterone acetate can effectively manage BPH and potentially improve fertility in affected dogs.
People also search for: dog prostatic hyperplasia treatment · osaterone acetate for dogs · dog semen quality improvement · zinc for dog fertility · dog prostate health
Abstract
Benign prostatic hyperplasia (BPH) may alter prostatic fluid biochemical composition causing reduced fertility. Osaterone acetate (OA) is an androgen receptor antagonist marketed for treatment of canine BPH. Little information exists on effects of OA administration on biochemical composition of canine prostatic fluid and its role on fertility. The aim of this research was to study biochemical composition of prostatic fluid and its role on semen quality in dogs with BPH undergoing treatment with OA. Eight intact, 5-11-year-old dogs with benign prostatic hyperplasia were treated orally with OA at a dose of 0.25-0.5 mg/kg once daily for seven days. Prostatic volume, semen evaluation and a biochemical analysis of prostatic fluid were performed on the day before treatment (D0), D60, D120, D180 and D240. A significant reduction (57% and 61%) of prostatic volume was observed at D60 and D120, respectively, and a significant reduction (20%) of normal spermatozoa was observed at D60 coincident with a significant increase of sperm tail defects, which disappeared during the course of the treatment. Prostatic fluid composition did not vary during the OA treatment except for zinc (Zn) with a significant increase at D120 and D180 correlated with the return to normal sperm values. In conclusion, canine Znprostatic fluid concentrations decrease during development of BPH and return to normal during treatment with OA. Znis an important electrolyte for semen quality, suggesting that oral Znsupplementation might be considered a treatment to improve semen quality.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34706118/